scholarly journals A First Step to a Biomarker of Curative Surgery in Colorectal Cancer by Liquid Biopsy of Methylated Septin 9 Gene

2020 ◽  
Vol 2020 ◽  
pp. 1-5
Author(s):  
M. Leon Arellano ◽  
M. García-Arranz ◽  
R. Ruiz ◽  
R. Olivera ◽  
S. Magallares ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Promoter Region ◽  
Methylation Status ◽  
Complete Resection ◽  
Peripheral Blood Sample ◽  
Curative Surgery ◽  
Septin 9 ◽  
Circulating Free Dna ◽  
Number Of Patients ◽  
Positive Results

Objectives. To confirm that patients affected by colorectal cancer have the V2 region of Septin 9 (SEPT9) gene hypermethylated in the circulating free DNA from a peripheral blood sample before surgery and to determine if this hypermethylated DNA disappears from the patients after complete resection of the tumour. Methods. Plasma from 10 patients with colorectal cancer was collected preoperative and three months after surgery. The analysis of the methylation status of the promoter region of the SEPT9 gene was performed using a 7500 Fast Real-Time PCR System. Results. Hypermethylation of SEPT9 gene was detected in 8 out of 10 preoperative samples (one negative result was probed to be a Lynch syndrome) and in 4 out of 10 postoperative samples matching with the cases of recurrence or persistence of disease. This means that, in this sample, the preoperative sensitivity and specificity of the test were 88.9% and 100%, respectively, and there is 100% correlation between the positive results of the SEPT9 test and a recurrence/persistence of the disease in patients after surgical resection. Conclusions. Our study shows that circulating hypermethylated SEPT9 is a specific colorectal cancer biomarker. This hypermethylated SEPT9 DNA disappears around three months after surgery and that circulating hypermethylated SEPT9 may be the first noninvasive marker for postsurgical diagnosis; this conclusion must be confirmed with a more significant number of patients.

scholarly journals Hypermethylated miR-424 in Colorectal Cancer Subsequently Upregulates VEGF

2021 ◽  
Author(s):  
Zahra Nouri Ghonbalani ◽  
Shiva Shahmohamadnejad ◽  
Parvin Pasalar ◽  
Ehsan Khalili
Keyword(s):  
Colorectal Cancer ◽  
Cancer Cells ◽  
Cancer Progression ◽  
Promoter Region ◽  
Hct116 Cell ◽  
Methylation Status ◽  
Expression Level ◽  
Cancer Tissue ◽  
Vegf Expression ◽  
Cancer Tissues

Abstract PurposeColorectal cancer (CRC) is the second leading cause of death from cancer in adults. Recent advances have shown that cancer cells can have some epigenetic changes involved in all stages of cancer. It has also been shown that miR-424 acts as gene expression regulators in many biological processes, including angiogenesis with mediators such as VEGF. In the current study, to identify the potential role of miR-424 in colorectal cancer progression, methylation status of miR-424 promoter region and its expression level have been evaluated. Besides, the correlation between VEGF level and miR-424 expression level has been assessed.MethodsMethylation status miR-424 promoter was assessed using methylation-specific polymerase chain reaction (MSP). The expression level of miR-424 in human colorectal cancer tissue was analyzed by quantitative PCR. HCT116 cell line was selected to evaluate the correlation between the miR-424 expression level and the promoter's methylation status. VEGF expression, one out of mir-424 targets involved in angiogenesis and cancer progression, was measured by western blot analysis in the pairs of cancer tissues and their adjacent tissues.ResultsOur results have revealed that the promoter region of miR-424 is methylated in cancer cells compared to normal cells, leading to down-regulation of miR-424 in the colorectal cancer tissues compared to the normal tissues. Also, we found that the expression protein's level of VEGF in the tumor cells increased compared with normal tissues.ConclusionThe present study suggests that hypermethylation downregulates miR-424. VEGF expression is upregulated with decreased miR-424 in colorectal cancer, which results in cancer progression.

scholarly journals The impact of COVID-19 pandemic on colorectal cancer patients: a single-center retrospective study

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Yun Xu ◽  
Zong-Hao Huang ◽  
Charlie Zhi-Lin Zheng ◽  
Cong Li ◽  
Yu-Qin Zhang ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Patients ◽  
Major Complication ◽  
Control Group ◽  
Endoscopic Polypectomy ◽  
Curative Surgery ◽  
Neoadjuvant Radiotherapy ◽  
Number Of Patients ◽  
Colorectal Cancer Patients ◽  
The Impact

Abstract Background Since December 2019, China has experienced a public health emergency from the coronavirus disease, which has become a pandemic and is impacting the care of cancer patients worldwide. This study evaluated the impact of the pandemic on colorectal cancer (CRC) patients at our center and aimed to share the lessons we learned with clinics currently experiencing this impact. Methods We retrospectively collected data on CRC patients admitted between January 1, 2020 and May 3, 2020; the control group comprised patients admitted between January 1, 2019 and May 3, 2019. Results During the pandemic, outpatient volumes decreased significantly, especially those of nonlocal and elderly patients, whereas the number of patients who received chemotherapy and surgery remained the same. During the pandemic, 710 CRC patients underwent curative resection. The proportion of patients who received laparoscopic surgeries was 49.4%, significantly higher than the 39.5% during the same period in 2019. The proportion of major complication during the pandemic was not significantly different from that of the control group. The mean hospital stay was significantly longer than that of the control group. Conclusions CRC patients confirmed to be infection-free can receive routine treatment. Using online medical counseling and appropriate identification, treatment and follow-up can be effectively maintained. Adjuvant and palliative chemotherapy should not be discontinued. Endoscopic polypectomy, elective, palliative, and multidisciplinary surgeries can be postponed, while curative surgery should proceed as usual. For elderly CRC patients, endoscopic surgery and neoadjuvant radiotherapy are recommended.

Abstract PO-019: DNA methylation status in a promoter region of the K-RAS gene in patients with Colorectal Cancer

2020 ◽  
Author(s):  
Jehison Alirio Herrera-Pulido ◽  
Orlando Ricaurte-Guerrero ◽  
Jinneth Acosta-Forero ◽  
Pablo Moreno-Acosta ◽  
María Carolina Sanabria-Salas ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Dna Methylation ◽  
Promoter Region ◽  
Methylation Status ◽  
Ras Gene

Conversion from unresectable to resectable liver metastases in real-world patients with liver-only metastatic colorectal cancer (mCRC) treated with FOLFOXIRI plus bevacizumab: The Conversion trial.

2021 ◽  
Vol 39 (3_suppl) ◽  
pp. TPS147-TPS147
Author(s):  
Shahid Ahmed ◽  
Deborah Anderson ◽  
Haji I. Chalchal ◽  
Lynn Dwernychuk ◽  
Dilip Gill ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cost Effectiveness ◽  
Liver Metastases ◽  
Real World ◽  
Fdg Pet ◽  
Conversion Rate ◽  
Curative Surgery ◽  
Number Of Patients ◽  
Pet Ct ◽  
Fdg Pet Ct

TPS147 Background: Patients with mCRC generally have a limited life expectancy, however, a small number of patients with liver-only mCRC could be cured following metastasectomy. In highly selected patients with mCRC, FOLFOXIRI (5FU, oxaliplatin, and irinotecan) plus bev results in high response rates. However, very limited evidence is available about efficacy of this regimen in real-world patients with liver-only mCRC. Furthermore, there is paucity of biomarkers that predict liver metastasectomy in such patients. The current study aims a) to evaluate rate of conversion from unresectable to resectable liver metastases in real-world patients with liver-only mCRC following FOLFOXIRI-bev, b) to identify predictive markers including an early PET-FDG response that correlate with curative surgery, & c) to determine disease control rate, overall survival, quality of life, treatment toxicities, and cost-effectiveness of surgery. Methods: In this pragmatic phase 2 study, 37 patients with liver-only unresectable mCRC who are deemed eligible for FOLFOXIRI-bev by their oncologist will be recruited at the two major cancer centers in Saskatchewan. Patients will receive FOLFOXIRI-bev every two weeks for a total of 12 cycles and will undergo periodic imaging tests. The resectability of liver metastases will be determined by a multidisciplinary team. For those patients who are not able to undergo a curative surgery, a doublet chemotherapy regimen ±bev will be continued at the discretion of treating oncologist. . The prognostic and predictive value of mutations in specific genes involved in cell proliferation, cell death resistance, angiogenesis, and invasion in colorectal cancer along with the relationship between the abundance and characteristics of exRNA and conversion rate and survival will be assessed. Logistic regression and Cox proportional analyses will be performed to assess correlation between an eight-week FDG-PET/CT response to chemotherapy and other biomarkers and rate of removal of metastases and survival, respectively. This pragmatic study will help to determine conversion rate in real-world patients with FOLFOXIRI plus bev and role of early FDG-PET/CT scan response and other biomarkers in predicting metastasectomy along with cost-effectiveness of this approach. Clinical trial information: NCT03401294.

Tu1929 Detection of Locally Methylated Septin 9 of Colorectal Cancer and Adenoma in Peripheral Blood Is Related to Circulating Free DNA Amount

2013 ◽  
Vol 144 (5) ◽  
pp. S-883
Author(s):  
Béla Molnár ◽  
Kinga Tóth ◽  
Ferenc Sipos ◽  
Katalin Leiszter ◽  
Alexandra Kalmár ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Peripheral Blood ◽  
Dna Amount ◽  
Septin 9 ◽  
Circulating Free Dna ◽  
Free Dna

scholarly journals The impact of COVID-19 pandemic on colorectal cancer patients: A single-center retrospective study

2020 ◽  
Author(s):  
Yun Xu ◽  
Zong-Hao Huang ◽  
Charlie Zhi-Lin Zheng ◽  
Cong Li ◽  
Yu-Qin Zhang ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Laparoscopic Surgery ◽  
Cancer Patients ◽  
Lessons Learned ◽  
Control Group ◽  
Endoscopic Polypectomy ◽  
Curative Surgery ◽  
Neoadjuvant Radiotherapy ◽  
Number Of Patients ◽  
The Impact

Abstract Background: Since December 2019, China has experienced the public health emergency of coronavirus disease, which has expanded globally and is impacting the care of cancer patients. This study evaluated the impact of the pandemic on colorectal cancer (CRC) patients at our center and aimed to share lessons learned with clinics currently experiencing this impact. Methods: We retrospectively collected data on CRC patients admitted between January 1, 2020 and May 3, 2020; the control group comprised patients admitted between January 1, 2019 and May 3, 2019. Results: During the pandemic, outpatient volumes decreased significantly, especially among nonlocal and elderly patients, whereas the number of patients who received chemotherapy and surgery were maintained. During the pandemic, 710 CRC patients underwent curative enterectomy. The proportion of laparoscopic surgery was 49.4%, which was significantly higher than the 39.5% patients who received a laparoscopic surgery during the same period in 2019. The proportion of major complication during the pandemic was not significantly different from that of the control group. The mean hospital stay was significantly longer than that of the control group. Conclusions: CRC patients who are confirmed to be infection-free can receive routine treatment. Using online medical counseling and appropriate identification, treatment and follow-up was effectively maintained. Adjuvant and palliative chemotherapy should not be discontinued. Endoscopic polypectomy, elective, palliative, and multidisciplinary surgeries can be postponed, whereas curative surgery should be performed. For elderly CRC patients, endoscopic surgery and neoadjuvant radiotherapy are recommended.

scholarly journals Pre-operative Targeted Therapies in Patients with Hepatic Colorectal Cancer Metastases—Bevacizumab versus Cetuximab

2010 ◽  
Vol 06 ◽  
pp. 42
Author(s):  
Francine Aubin ◽  
Charles D Blanke ◽  
◽  
Keyword(s):  
Colorectal Cancer ◽  
High Risk ◽  
Targeted Therapies ◽  
Current Data ◽  
Complete Resection ◽  
Curative Surgery ◽  
Colorectal Cancer Liver Metastases ◽  
Cancer Metastases ◽  
Neoadjuvant Systemic Therapy ◽  
Colorectal Cancer Metastases

Complete resection offers the greatest chance of cure for patients with isolated colorectal cancer liver metastases. While few patients present as candidates for curative surgery, induction chemotherapy may make patients with initially unresectable disease amenable to surgery. Even those whose disease is potentially curable at presentation may benefit from pre-operative neoadjuvant systemic therapy, particularly those deemed at high risk for relapse. Biological targeted therapies such as bevacizumab and cetuximab improve on standard systemic chemotherapeutic regimens in incurable patients; the rationale for their pre-operative use is also strong. Uncertainties remain as to which (if either) agent to preferentially use and their ultimate role in this setting must be better defined. This article reviews the concepts behind, and current data on, the use of pre-operative cetuximab and bevacizumab in patients with hepatic colorectal cancer metastases.

scholarly journals The Impact of COVID-19 Pandemic on Colorectal Cancer Patients: A Single-Center Retrospective Study

2020 ◽  
Author(s):  
Yun Xu ◽  
Zong-Hao Huang ◽  
Charlie Zhi-Lin Zheng ◽  
Cong Li ◽  
Yu-Qin Zhang ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Laparoscopic Surgery ◽  
Cancer Patients ◽  
Lessons Learned ◽  
Control Group ◽  
Endoscopic Polypectomy ◽  
Curative Surgery ◽  
Neoadjuvant Radiotherapy ◽  
Number Of Patients ◽  
The Impact

Abstract Background: Since December 2019, China has experienced the public health emergency of coronavirus disease, which has expanded globally and is impacting the care of cancer patients. This study evaluated the impact of the pandemic on colorectal cancer (CRC) patients at our center and aimed to share lessons learned with clinics currently experiencing this impact. Methods: We retrospectively collected data on CRC patients admitted between January 1, 2020 and May 3, 2020; the control group comprised patients admitted between January 1, 2019 and May 3, 2019. Results: During the pandemic, outpatient volumes decreased significantly, especially among nonlocal and elderly patients, whereas the number of patients who received chemotherapy and surgery were maintained. During the pandemic, 710 CRC patients underwent curative enterectomy. The proportion of laparoscopic surgery was 49.4%, which was significantly higher than the 39.5% patients who received a laparoscopic surgery during the same period in 2019. The proportion of major complication during the pandemic was not significantly different from that of the control group. The mean hospital stay was significantly longer than that of the control group. Conclusions: CRC patients who are confirmed to be infection-free can receive routine treatment. Using online medical counseling and appropriate identification, treatment and follow-up was effectively maintained. Adjuvant and palliative chemotherapy should not be discontinued. Endoscopic polypectomy, elective, palliative, and multidisciplinary surgeries can be postponed, whereas curative surgery should be performed. For elderly CRC patients, endoscopic surgery and neoadjuvant radiotherapy are recommended.Trial registration: retrospectively registered

Sign in / Sign up

Export Citation Format

Share Document